Loading
Trials that fail still collected thousands of blood and tissue samples. Instead of being destroyed, they should be pooled so scientists can learn who might have benefited.
Negative trials are often the most informative for biomarker discovery: a subgroup may have responded. Samples from discontinued programmes are usually destroyed or locked. A biobank with pre-negotiated transfer terms, linked de-identified clinical data, and an access committee would allow prospective-retrospective biomarker studies and could resurrect drugs for a biomarker-defined population.
Shares A commons of shelved cancer drugs with their full data, open to new hypotheses, Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.